EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Announces Amendment to its Existing Credit Facility

30 апр 2024 17:26:55 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

22 апр 2024 08:05:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

28 мар 2024 08:15:03 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

25 мар 2024 08:05:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

06 мар 2024 16:31:01 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

29 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

21 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

11 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

09 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

28 ноя 2023 06:59:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

24 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Reports Third Quarter 2023 Financial Results

08 ноя 2023 17:38:16 Источник Nasdaq GlobeNewswire

UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023

30 окт 2023 16:45:13 Источник Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023

19 окт 2023 06:30:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

02 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

30 авг 2023 05:59:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Second Quarter 2023

08 авг 2023 16:31:58 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position

08 авг 2023 07:15:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola

31 июл 2023 16:05:00 Источник Nasdaq GlobeNewswire

Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

20 июл 2023 18:03:20 Источник Nasdaq GlobeNewswire